Inve India ▾

Cipla share price & results

Cipla Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

India's 3rd-largest drugmaker; sells generics, inhalers and consumer health across 74 markets

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue5,067 ₹ crore−3.0% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin22.0 %−7.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit787 ₹ crore−35.0% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity8.78 %−6.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.30 %−9.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-0.74 %−4.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

3 of 4 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.

Cipla Limited management guidance track record on Inve: 15 targets tracked across analysed earnings calls (3 achieved, 1 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
Product Supplyresume in H1 FY'27
Call transcript, Q3 FY26 · 23 Jan 2026		Q3 FY26Q1 FY27:Management states the timing is 'a little bit fluid' and dependent on regulatory approvals, confirming the delay beyond FY27. No contribution is included in projections.
Call transcript, Q1 FY27 · 23 Jul 2026		Delayed
Product Launch2 to 3 peptide assets in FY '26
Call transcript, Q4 FY25 · 13 May 2025		Q4 FY25Q1 FY27:Management confirmed 'one peptide, which is large' is among the key upcoming launches for FY27, keeping the delayed promise on track.
Call transcript, Q1 FY27 · 23 Jul 2026		On Track

Source: Inve Guidance Tracker for Cipla Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

1 of Cipla Limited's 15 targets was missed. See which ones, and which are quietly gone. The 2 above are the free sample; 13 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,350 −0.37% · −₹5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −14.8% 1Y

₹1.2k₹1.3k₹1.4k₹1.5k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 30 Oct 2025Q3 FY26 — 23 Jan 2026Q4 FY26 — 13 May 2026Q1 FY27 — 23 Jul 2026

1Y: ₹1,584.4 on 24 Oct 2025 → ₹1,350. High ₹1,584.4 (24 Oct 2025), low ₹1,192.4 (2 Apr 2026).

Previous close
₹1,355
Market cap
₹1.1L Cr
52-week range
₹1,192.4 – ₹1,584
One year
−14.77%
Price to earnings (TTM to Sept 2026)
35.15×
Return on equity (TTM to Sept 2026)
8.78%

Overview

Symbol
NSE:CIPLA
Exchange
NSE
Currency
INR

What Cipla Limited does

Based on the company's own presentations, annual report and earnings calls.

Founded in 1935, Cipla is a global pharmaceutical company that develops, manufactures and markets branded prescription drugs, trade generics and consumer-health products. It earns across four regional businesses — One India, North America, One Africa and Emerging Markets & Europe — spanning respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS therapies. Its manufacturing network produces over 50 dosage forms and more than 1,500 products, and it is the fourth-largest player by prescription for generic inhalation products in the US.

Segments

  • One India
  • North America
  • One Africa
  • Emerging Markets & Europe
  • API & Others
Manufacturing sites worldwide
46
Markets served
74
Products manufactured
1,500+ across 50+ dosage forms
ANDAs & NDAs (as on 31 Mar 2026)
285 total (181 approved, 49 tentatively approved, 55 under approval)
Rank in Indian pharma market
No.3 in India; No.2 in South Africa prescription market
India Trade Generics position
No.1 (India's largest trade generic business)
Founded 1935Headquarters Mumbai, India Company website

How the price took the results

close before → close after

Q1 FY27
−1.6%
23 Jul
Q4 FY26
+2.7%
13 May
Q3 FY26
−4.0%
23 Jan
Q2 FY26
−2.6%
30 Oct

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Cipla Limited

Free account: one company. Everything above stays public.

Write why you follow Cipla Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Cipla Limited

Guides on how to read this kind of business and the numbers that matter.